Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa
This study presents evidence that switching from alglucosidase to avalglucosidase may be associated with improved outcomes in certain patients with LOPD.
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Back Pain | Brain | Disability | Genetics | Low Back Pain | Neurology | Pain | Pulmonary Function Testing | Statistics | Study